TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60 years old~* In the hospital setting \>24 hours for the management of ADHF, or diagnosed with ADHF after being hospitalized for another reason. ADHF will be confirmed by the study physician, and will be defined according to the Food and Drug Administration definition of hospitalized heart failure as a combination of symptoms, signs, and HF-specific medical treatments.~Exclusion Criteria:~* Acute myocardial infarction~* Planned discharge other than to home or a facility where the participant will live independently~* Already actively participating in formal, facility-based cardiac rehabilitation

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Attention Control (Type: OTHER): Usual care group with bi-weekly contact from study staff
- multi-domain rehabilitation intervention (Type: ACTIVE_COMPARATOR): Individual, tailored, progressive, physical function rehabilitation intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Uterine Artery Ligation in Reducing Incidence of Postpartum Hemorrhage in Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with one or more of the following conditions undergoing cesarean section for obstetric indication were included:~* Maternal anemia (not less than 7 gm %).~* Macrosomic baby \>4kgs.~* Twin pregnancy and high order pregnancy.~* Polyhydramnios.~* Grand multipara.~* Previous history of atonic postpartum hemorrhage.~* Prolonged vaginal delivery.~* Emergency cesarean.~* Chorioamnionitis.~Exclusion Criteria:~* - Placenta previa.~* Patients with bleeding tendency (congenital or acquired)~* Ante-partum hemorrhage.~* Patients with no risk for uterine atony.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
- control group (Type: ACTIVE_COMPARATOR): patients at risk of uterine atony undergoing cesarean section received oxytocin only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Implementation of the HiBalance Program in Clinical Practice

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed idiopathic Parkinson's Disease~* Measured balance impairment (according to the mini-BESTest)~* Hoehn and Yahr stages 2-3~* Independent ambulator indoors without a walking aid~Exclusion Criteria:~* Cognitive impairment which hinders participation in group training~* The presence of comorbidities which hinder safe participation in group training

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balance training group (Type: EXPERIMENTAL): 1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
- Control group (Type: NO_INTERVENTION): Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study in Japanese Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inpatients or outpatients with type 2 diabetes, aged 20 years or older, on insulin therapy who have planned to change insulin therapy during the registration period of the study~* Patients who have provided written informed consent to participation in the study after receiving explanations about the objective and other details of the study~* Patients who have received the same insulin therapy for 3 months or longer before informed consent. (i.e. receiving the same type of insulin preparation at the same dosing frequency regardless of insulin dose)~Exclusion Criteria:~* Patients who have planned to discontinue insulin therapy~* Patients incapable of completing the ITR-QOL, DTSQ and patient's questionnaire based on their self-ratings~* Patients with type 1 diabetes~* Patients who have used CSII or have planned to switch to CSII(continuous subcutaneous insulin infusion )~* Patients with poor treatment compliance as determined by their investigators based on the treatment history

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type 2 diabetes treated with insulin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Singing and Cardiovascular Health in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* English Speaking~* Have a history of coronary artery disease (defined as history of myocardial infarction, coronary stenosis \>50%, percutaneous coronary intervention with stent placement, balloon angioplasty, or coronary arterial bypass grafting)~Exclusion Criteria:~* Subjects with a permanent pacemaker or implantable cardioverter defibrillator (ICD) implanted~* Patients with a history of atrial fibrillation, flutter or atrial tachycardia~* Parkinson's disease or a tremor~* Amputated upper extremity or presence of upper-arm (dialysis) fistula~* Fingernail onychomycosis (fungal infections resulting in thickening of the nails)~* Pregnancy~* Current illicit drug use (marijuana, tobacco, cocaine, amphetamines, etc.)~* Current excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men)~* Unstable coronary heart disease (active symptoms of chest discomfort)~* History of a Stroke or TIA or peripheral arterial disease~* Known history of cognitive impairment or inability to follow study procedures~* Cancer requiring systemic treatment within five years of enrollment.~* Subjects requiring supplemental oxygen use~* Non-English speaking subjects (video with lyrics are taped in English)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Singing intervention 1 (Type: ACTIVE_COMPARATOR): Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
- Singing intervention 2 (Type: ACTIVE_COMPARATOR): In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
- Control/sham intervention (Type: SHAM_COMPARATOR): Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of gMG \[Myasthenia Gravis Foundation of America (MGFA) Class II-IV\] at Screening~* Positive serology for acetylcholine receptor (AChR) autoantibodies~* MG-ADL Score of ≥ 6 at Screening and Baseline~* QMG score ≥ 12 at Screening and Baseline~* No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period~* No change in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period~Exclusion Criteria:~* Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12 week Treatment Period~* History of meningococcal disease~* Current or recent systemic infection within 2 weeks prior to Baseline or injection requiring intravenous (IV) antibiotics within 4 weeks prior to Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 0.3 mg/kg zilucoplan (RA101495) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nebulized Bronchodilators on Heart Rate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults who required inhaled bronchodilator therapy in the form of short acting beta adrenergic receptor agonist and short acting anti-cholinergic treatment every 4-6 hours for respiratory functions~Exclusion Criteria:~* Known allergy or sensitivity to study medications~* Baseline heart rate was greater than 110 beats per minute

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levalbuterol 0.63 (Type: ACTIVE_COMPARATOR): Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
- Levalbuterol 1.25 (Type: ACTIVE_COMPARATOR): Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Treatment of Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* nonviable intrauterine pregnancy with retained gestational sac in the uterus~* the embryo if visible 5 to 35 mm without a heart beat~* vaginal bleeding~* circulatory stable~* hemoglobin at least 80 g/L~Exclusion Criteria:~* contraindications against misoprostol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misoprostol 800 micrograms intravaginally (Type: EXPERIMENTAL): None
- expectant managment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-cholesterol between 130 - 189 mg/dL at screening following washout of all LDL-C-lowering drugs and nutritional supplements~* Men and nonpregnant, nonlactating women~* Sufficiently stable and suitable to undergo washout of all LDL-C-lowering drugs and nutritional supplements for 12 weeks~Exclusion Criteria:~* Fasting blood triglycerides greater than or equal to 400 mg/dL~* Body Mass Index (BMI) greater than 50 kg/m2~* History of clinically significant cardiovascular disease~* History of type 1 or type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triplet Therapy (Type: EXPERIMENTAL): Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
- placebo (Type: PLACEBO_COMPARATOR): Matching placebos taken orally, daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age~* Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay.~* Is treatment naive or has received prior treatment for metastatic melanoma.~* Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).~* Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment.~* Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.~* Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.~* Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~* Adequate organ function.~Exclusion Criteria:~* Previous treatment with a BRAF or MEK inhibitor.~* Cancer therapy (chemotherapy with delayed toxicity, radiation therapy, immunotherapy, biologic therapy, or major surgery) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks; or use of any investigational anti-cancer or other drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of GSK2118436.~* A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.~* History or evidence of brain metastases on MRI or head CT if MRI is not able to be performed.~* History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Certain cardiac abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: OTHER): Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. The infant is being managed for NOWS at an eligible site (i.e., receiving non-pharmacologic care, assessments for withdrawal severity, +/- pharmacologic care) 2. The infant is ≥ 36 weeks gestation 3. The infant satisfies at least 1 of the following criteria:~  1. Maternal history of prenatal opioid use~ 2. Maternal toxicology screen positive for opioids during the second and/or third trimester of pregnancy~ 3. Infant toxicology screen positive for opioids during the initial hospital stay~Exclusion Criteria:~* 1. Infant has major birth defect(s) 2. Infant has neonatal encephalopathy (inclusive of hypoxic ischemic encephalopathy), a metabolic disorder, stroke, intracranial hemorrhage, or meningitis diagnosed by 60 hours of life 3. Infant was receiving respiratory support (any positive pressure or oxygen therapy) unrelated to pharmacologic treatment for NOWS at 60 hours of life 4. Infant was receiving antimicrobial(s) at 60 hours of life 5. Infant has received any major surgical intervention in the first 60 hours of life 6. Postnatal opioid exposure other than for treatment of NOWS in the first 60 hours of life 7. Outborn infants transferred at \>60 hours of life or treated with opioids for NOWS at the transferring hospital

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Usual care, Finnegan Neonatal Abstinence Scoring Tool (Type: ACTIVE_COMPARATOR): Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
- Eat, Sleep, Console care tool (Type: ACTIVE_COMPARATOR): New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed with human immunodeficiency virus type 1 (HIV-1) evidenced by any of the following within 2 weeks of the screening/baseline visit: a) HIV Rapid Antibody positive; or b) HIV Immunoassay positive; or c) Positive p24 antigen and a HIV-1 ribonucleic acid (RNA) viral load greater than or equal to (\>=) 5,000 copies per milliliter (copies/ mL); or d) Non-reactive HIV-1 antibody/antigen assays and HIV-1 RNA viral load (\>=) 5,000 copies/mL. HIV-1 RNA viral load must be confirmed once within 1 week of initial HIV-1 RNA viral load test~* Antiretroviral treatment-naïve, except for the use of TRUVADA® for pre-exposure prophylaxis (PrEP)~* Must be able to swallow whole tablets~* A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 90 days after receiving the last dose of study drug~* A woman of childbearing potential must have a negative urine pregnancy test at screening~Exclusion Criteria:~* Known active cryptococcal infection, active toxoplasmic encephalitis, Mycobacterium tuberculosis infection, or another acquired immunodeficiency syndrome (AIDS) -defining condition that in the judgement of the investigator would increase the risk of morbidity or mortality~* Known history of clinically relevant hepatic disease or hepatitis that in the investigator's judgement is not compatible with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF FDC)~* Known history of cirrhosis as diagnosed based on local practices~* Known history of chronic (\[\>=\] 3 months) renal insufficiency, defined as having an estimated glomerular filtration rate (eGFR) less than (\<) 50 milliliter per minute (mL/min) according to the Modification of Diet in Renal Disease (MDRD) formula~* Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC (Type: EXPERIMENTAL): Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete